November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at email@example.com)
January 26, 2015
Russian Defense Ministry says Mariupol-related video by Ukraine Security Service a fake
Roscosmos plans to reassess short-term, long-term priorities - chief
Ukraine goes over to offensive - Donetsk People's Republic official
S&P lowers Russia's rating, depriving it of investment grade
Ukraine's preconditions for heavy weaponry pullout a dead-end option - Russian source (Part 2)
PACE report on humanitarian situation in Donbas biased - Russian senator
Donetsk republic says has established control over two towns in 24 hours
Sanctions have had no impact on joint space projects - Roscosmos chief (Part 2)
S&P CUTS RUSSIA sovereign credit RATING TO BB+ FROM BBB-
More of Donetsk infrastructure damaged as shelling continues
Putin: Anti-crisis plan must be discussed with lawmakers within week (Part 2)
Putin: Anti-crisis plan must be discussed with lawmakers within week
Putin meeting with Cabinet members, Central Bank, Audit Chamber heads